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ABSTRACT 
 
Hallucinogens are drugs that alter consciousness by distorting primarily 
auditory and visual perception but they can affect any sensory system.  
Hallucinogens also affect judgment, orientation, memory, or emotion. Despite the 
profound alteration in perception, adverse effects are minimal and hallucinogens 
are not addictive.  Hallucinogen use has its roots in shamanic practices of 
indigenous cultures and is even incorporated in today’s religions like the Native 
American Church. By putting a person in an altered state of consciousness, 
many religions believed that the user was able to see beyond the boundaries of 
reality and reach out to mythical beings. Hallucinogen use in scientific research 
was not popular until the 1950’s when Albert Hoffman discovered lysergic acid 
diethylamide (LSD). The discovery of drug encouraged further research into 
understanding its mechanisms and its relationship with mental diseases like 
schizophrenia. Unfortunately, the Comprehensive Drug Abuse Prevention and 
Control Act of 1970 significantly limited hallucinogenic research and human 
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research for the last 42 years. However, animal research in the last 20 years has 
determined the importance of serotonergic mechanisms and more specifically the 
5-HT2A receptors in mediating LSD’s hallucinogenic effects. Researchers 
continue to identify mechanisms of LSD action. In addition to serotonergic 
actions, LSD is active with dopaminergic and metabotropic glutamate receptors. 
PET scans and fMRI’s have also revealed the importance of the prefrontal 
cortical region and its interaction with other areas during a hallucinogenic state. 
The relationship between LSD and acute psychosis is also being explored via 
animal models. Although human clinical research is limited, recent research sees 
a much deeper relationship by linking LSD brain activity and neurotransmitter 
levels to psychotic behaviors. This further understanding of hallucinogens on a 
physiological and psychological level has led to possible psychotherapeutic 
areas of research in anxiety and substance abuse. This thesis describes a brief 
history of hallucinogenic research, the pharmacology and neuroanatomy of 
serotonergic hallucinogens, the acute and chronic adverse effects of serotonergic 
hallucinogens, the possible treatments for complications of hallucinogens, the 
epidemiology, the relationship between hallucinogens and schizophrenia, and 
possible therapeutic uses of serotonergic hallucinogens.  
With its minimal adverse effects in humans and its powerful influence on 
the human psyche, serotonergic hallucinogens are invaluable tools for 
understanding the human mind. 
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Introduction 
 Hallucinogens are drugs that alter consciousness by inducing sensory and 
perceptual disturbances.  Distorted perceptions of visual and auditory stimuli 
occur most commonly but tactile, gustatory and olfactory distortions can also 
occur.  A phenomenon called synesthesia is a combination of sensory distortions 
where sounds are “seen’” or colors are “heard”.1 Hallucinogens also induce 
intense emotional responses that can affect judgment, orientation and memory.  
However, the term “hallucinogen” can be misleading because it is not common 
for users to experience true hallucinations such as manifestations of something 
non-existent.  Instead, users experience illusions or a perceptual distortion of 
normal environmental stimuli.2 Although hallucinogens are relatively non-toxic, 
even in experienced users, they can produce dramatic effects that often have 
unpredictable variability in onset, duration and intensity.  Non-drug factors such 
as the “set and setting”, where hallucinogens are used, can alter the experience 
and produce adverse effects in even highly experienced users.1 
Because hallucinogen is an umbrella term and almost any drug can 
produce sensory or perceptual distortions, this paper describes drugs that are 
indolealkylamines (see Figures 1,2,3 for common drugs associated).  These 
drugs share structural similarities to serotonin and act through activation of 
specific serotonin receptors.1  Phenethylamines are structurally similar to the 
monoamines, dopamine, norepinephrine, and epinephrine that have 
 
2 
predominately stimulant effects.  The phenylisopropylamines are unique because 
they share both stimulant and sensory distorting properties. They are sometimes 
referred to as “stimulant hallucinogens”.  Because phenylisopropylamines are 
often synthesized to evade drug control laws or produce a particular form of 
intoxication, they are also called designer drugs.3  Over the last 40 years, 
numerous analogues of substituted phenethylamines and phenylisopropylamines 
have been introduced to the public, reflecting both the ingenuity of underground 
medicinal chemists and the continuing appeal of hallucinogens to society.  
Many drugs produce sensory distortions, but for purposes of this thesis, I 
focus on serotonergic hallucinogens.  There are four major drugs in this group: 
psilocin, psilocybin, dimethyl tryptamine (DMT), and lysergic acid diethylamide 
(LSD).  All share an indolealkyamines structure that is similar to the serotonin 
neurotransmitter (5-hydroxytrptamine).  This structure consists of a common 
indole moiety with an alkyl group that stretches out for 2 carbons. The amine side 
chain is basic and varies from primary to tertiary depending on the substance. Of 
these four serotonergic hallucinogens, LSD is the most widely studied as the 
prototype for this class. 
 Hallucinogens are also known as “psychedelics”, a term Osmond coined 
to describe the more “mind manifesting” aspects of the user experience.4 
Whatever the label, drugs that distort sensations have been associated with 
spiritual and religious enlightenment with roots in the shamanic practices of 
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indigenous cultures.5,6 However, the use of psychedelic plants is inversely 
correlated with the social and political complexity of societies according to 
Winkelman.5 A possible theory is that hallucinogens are seen as instruments of 
resistance to a centralized authority controlling society’s culture and attitude. On 
the other hand, societies that rely on a community as a foundation are more 
inclined to embrace these hallucinogenic tools for cohesion and mental 
awakening towards a set of beliefs. An example is the use of Banisteriopsis 
genus (Ayahuasca) in South American cultural practices that seek enlightenment 
and journey into one’s identity. Use of hallucinogens was vital for this culture in 
mediating concepts like group collectivism and reinforcing social order.5 Another 
example is the integration of peyote in the Navajo nation. In this society, 
hallucinogenic drugs were seen as a connection between the present and the 
past. Peyote was important in facilitating unity for this culture’s people and 
forming the current Native American Church.5 Even in Western civilization of the 
19th and 20th centuries, there is evidence linking psychomimetic mushroom use in 
Christian subcultures. This experience of an altered state of consciousness 
promotes mysticism where a person is able to see beyond the boundaries of 
reality. Many cultures believe these hallucinations promote a raw connection with 
nature and its environment. The use of hallucinogens was so common in the Old 
World and prehistoric times that some sociologists believe it played a part in the 
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development of the human consciousness and sparked the development of many 
religions.5 
These mind manifesting, altered states of consciousness and experiences 
have deeply affected modern neuroscience with scientists questing for both 
mechanisms and meanings of consciousness.  From the mid 20th century to the 
present, researchers have hoped that studying hallucinogens would provide a 
window into the genesis of severe psychiatric diseases such as the 
schizophrenias as well the neural basis of creativity, spirituality and sensory 
processing.  Coincident with scientific exploration, widespread public 
experimentation with hallucinogens, initially promoted by academic researchers, 
lead to a backlash that inhibited research with these agents.  We are just 
emerging from this period of scientific and cultural reticence to learn more about 
hallucinogens. 
 During the 1950’s, hallucinogens were studied as a method for inducing a 
temporary psychosis in normal people and were called “psychotomimetics” 
(producer of psychosis).4  The hope was that hallucinogens would aid in the study 
of psychosis and the schizophrenias, leading to an understanding of the 
pharmacology of these disorders.  By 1961, just prior to widespread abuse, there 
was a robust research effort with nearly 1,000 articles published.  However, 
scientific interest may have laid the foundation for emergence of hallucinogens 
as the talisman for pharmacological enlightenment of the 1960’s ‘counter culture’ 
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movement.  For example, Harvard psychologist Timothy Leary launched a 
movement built around the LSD experience. Discovered by Albert Hoffman in 
1943, LSD is a semi-synthetic derivative of a lysergic acid, a natural product of 
the ergot fungus called Clavicus Purprea. Its hallucinogenic influence did not 
come to light until it was introduced to Leary after he enjoyed using psilocybin at 
Harvard in 1960. Leary saw LSD as an opportunity to tap into the mythical 
consciousness and the enhancement of creativity and positive emotions, if used 
in a controlled manner.7 A couple years later, during his landmark 1966 counter 
culture speech that sought detachment from societal establishment and hierarchy 
with LSD as the solution, he coined the phrase “Turn on, tune in, drop out”. 
Increasing publicity and widespread availability of LSD contributed to an 
epidemic of use in a predominantly youth culture.7  
 In tandem with the increasing popularity of hallucinogens, other abusable 
intoxicants emerged including marijuana, heroin, cocaine, methamphetamine, 
methylenedioxymethamphetamine (MDMA).  The combination of wide spread 
abuse and media sensationalism resulted in a growing public consensus that 
viewed these drugs as a danger to society.2  In the United States, the outcome 
was the Comprehensive Drug Abuse Prevention and Control Act of 1970.  This 
law was the principle legislation enacted to prosecute President Nixon’s 
declaration of a War on Drugs.  Under this legislation, hallucinogens were 
classified in Schedule 1, which is the highest level of control in the United States.  
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By definition, Schedule 1 drugs have “no currently accepted medical use, a lack 
of accepted safety for use under medical supervision, and a high potential for 
abuse”.8 Scheduling hallucinogens increased barriers to basic and clinical 
research. Therefore, publication rates decreased and investigators moved to 
other models for problems of interest. The majority of American studies were 
reduced to animal models with the exception of Dr. Alexander Shulgin who 
conducted independent research without government or institutional assistance. 
His work focused on analogues of phenethylamines that he created. These drugs 
were tested on volunteers until the government shut down his activities by the 
late 1980’s. Although his work was very basic in analyzing the psychotomimetic 
effects, his theories on hallucinogen structure and activity are still invaluable.9 In 
1990, Dr. Rick Strassman attempted to conduct research with DMT (dimethyl 
tryptamine) by submitting an investigational drug application to the FDA. 
Strassman was interested in the possibility of DMT being produced in the human 
pineal gland and he wanted to administer small doses of the DMT to healthy, 
hallucinogenic experienced participants.  His submission was groundbreaking for 
psychedelic research because it was the first clinical experiment with a 
hallucinogen in more than 20 years.10 Despite a very small cadre of researchers 
in the U.S., the legacy of the 1970 law is that few human studies have occurred 
over the last 42 years, stifling research on mechanisms of neurologic and 
psychiatric disorders.  
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Pharmacology, Antagonists, and Neuroanatomy of Hallucinogen Action  
 
Pharmacology: Serotonergic Mechanism 
The family of serotonergic receptors has grown from the first two subtypes 
– 5-HT1 and 5-HT2, discovered by Peroutka and Snyder in 1970’s – to a total of 
14 receptors categorized into 7 families.12  LSD has a high receptor affinity for 
many subcategories of 5-HT receptors including the 5-HT1B, 5-HT1D, 5-HT7, 5-
HT6 but there is a fairly clear consensus that agonism at the 5-HT2A receptor 
mediates the effects of LSD.11,12 In both animal and human studies, modulation 
of 5-HT2A receptors appears to medicate the effects of LSD.  For example, in 
adult mice, LSD effects can be blocked by the highly selective 5-HT2A receptor 
antagonist M100907.13 A 2007 study with 5-HT2A receptor knockout mice saw a 
restoration of LSD behavior (head twitch response) when the receptor was 
genetically restored.14 Another study by Buckholtz compared chronic use of LSD 
against its nonhallucinogenic analogue bromo-LSD.  Density of 5-HT2A receptors 
was lower in the LSD treated rats, suggesting a molecular mechanism to explain 
the rapid development of tolerance to LSD and the importance of these 
receptors.15  In humans, Vollenweider tested the effects of oral ketanserin and 
risperidone given before 0.25 mg of oral psilocybin.16  He found these relatively 
non-selective 5-HT2A receptor blockers attenuated psilocybin effects. Although 
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the effects of 5-HT2A blockade on a human LSD experience have not been 
assessed, similar findings are likely.  
The post receptor pharmacology of LSD is complex due to its actions at G 
protein coupled receptors.   Agonism at the 5-HT2A receptor causes its 
attachment to the G protein (Gq/11), which elevates intracellular phospholipase C 
to hydrolyze PIP2 (phosphatidyl inositol 3,4 bisphosphate) into IP3 (inositol 1,4,5 
triphosphate) and DAG (diacylglycerol).  Both IP3 and DAG act as secondary 
messengers to trigger protein phosphorylation in the cell body. DAG activates 
protein kinase C to cause activation of the MAP kinase pathway. This pathway is 
responsible for promoting the transcription of the c-Fos protein and other growth 
factors in the nucleus and cytoplasm of cells. However, the LSD pathway 
stimulates PIP2 hydrolysis weakly and there has been speculation of an 
additional activation of the independent phospholipase A2 signaling pathway. The 
PLA2 pathway releases arachidonic acid from glycerol and is needed for 
hallucinogenic action.17    
The pharmacological mechanism of LSD’s action and other hallucinogens 
is far from settled.  For example lisuride, a structural analogue of LSD, is a 
dopamine and serotonin partial agonist that activates 5-HT2A receptors. Yet, it 
lacks hallucinogenic properties.12 To distinguish between the two substances, a 
2011 study by Halberstadt observed how lisuride and LSD disrupted pre-pulse 
inhibition (PPI), a measure of sensorimotor gating. While a selective 5-HT2A 
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antagonist attenuated only LSD’s PPI, a dopamine D2/D3 antagonist abated 
lisuride’s PPI, suggesting two different receptor pathways. 18 LSD also activates a 
pertussis sensitive heterotrimeric G protein and a tyrosine kinase protein SRC 
(often involved in cellular proliferation and growth) to stabilize a distinct 
conformation that is different from lisuride. 19 The concept that G protein 
receptors can have multiple agonist conformations has been advanced to explain 
these differences in pharmacologic effects.  
Although LSD is primarily associated with the 5-HT2A receptors, the drug’s 
affinity for the receptor as a weak agonist is similar to other hallucinogens that 
are 20-30 times less potent.20 This weak agonism suggests that LSD must 
activate other receptors but whether it is other serotonin receptors or a different 
receptor class is not yet clear. LSD acts on pyramidal 5-HT neurons, which have 
a complex pharmacology with several 5-HT receptors likely modulating 
hallucinogenic activity. All agents that activate 5-HT2A receptors also activate 5-
HT2C receptors and 5-HT2C receptors may also be needed to produce 
hallucinogenic effects.  In some rodent studies, compounds selective for the 5-
HT2C receptors appear more active than 5-HT2A compounds in producing 
hallucinogenic effects.12  Thus, although 5-HT2A receptors are needed for a 
hallucinogenic stimulus to progress, they might not be sufficient and require the 
additional contributions from the 5-HT2C receptors.  Adding complexity, the 
regulation of 5-HT receptors in pyramidal neurons is blocked when a 5-HT1A 
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antagonist is added.21  When both 5-HT1A and 2A receptor subtypes are co-
activated, there is selective enhancement of response to the stronger excitatory 
stimuli, indicating receptor competition in these pyramidal neurons.22  Lisuride 
has shown to be a strong 5-HT1A agonist and exhibits no hallucinogenic effect. Its 
strong promotion of 5-HT1A receptors probably leads to an inhibition of the 
hallucinogenic pathway over the excitatory hallucinogenic response of 5-HT2A 
receptors.23  
In addition to serotonergic agonism, LSD also modulates the activity of 
glutamate and dopamine receptors.  With glutamate, the metabotropic glutamate 
receptor 2 (mGluR2) dimerizes with 5-HT2A to form a receptor complex that goes 
down two different g-protein pathways depending on the ligand.24  In a mGluR2 
knockout study by Maeso, mGluR2-KO mice did not exhibit a hallucinogenic 
response to injections of LSD compared to the controls.25 It suggests that 
mGluR2 is necessary for the hallucinosis pathway by promoting a higher affinity 
conformation for hallucinogenic ligand binding to 5-HT2A as a receptor complex. 
However, activation of only mGluR2 using a glutamate agonist, LY379268, 
causes an increase of glutamate in the prefrontal cortex and a suppression of 
hallucinogen signaling.26,27 This g-protein (Gi/o) activates adenyl cyclase, which 
converts ATP to a secondary messenger called cAMP. As a secondary 
messenger, cAMP activates protein kinase A that phosphorylates many different 
proteins for an inhibitory response. This inhibitory response has a higher 
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prevalence at a normal basal metabolism.  A decrease in mGluR2 would 
maintain the pro-hallucinogenic pathway but limit suppression. With 
schizophrenia and serotonergic hallucinosis having many similarities in 
pathways, a postmortem study of schizophrenic patients showed high cortical 
densities of 5-HT2A receptors and low cortical mGluR2, providing further evidence 
for this mGluR2 theory.27 This theory of two competing G-protein pathways 
indicates that these receptors regulate each other and act as a signal gate for the 
cortex. It also suggests that these receptors have different responses as 
individual components than as a receptor complex.28 
LSD also has dopaminergic effects with D2 receptor binding at behaviorally 
relevant doses.12 Risperidone, a mixture of 5-HT2 and D2 antagonists, was more 
effective in blocking LSD discrimination in rats than ritanserin, which is a pure 5-
HT2A /5-HT2C antagonist by more than 414 times.29,30 Even the efficacy of 
ritanserin against LSD increases substantially when given with haloperidol, an 
inverse dopamine agonist.31 A recent 2011 study by Albizu provides evidence of 
a heteromer between D2 receptors and 5-HT2A receptors in HEK293 cells.32  
Efficacy of hallucinogen binding to the 5-HT2A receptor was increased when the 
D2 receptor was present and decreased after introducing quinprole, a D2 agonist 
(see Figure 9). Like mGluR2 receptors, D2 receptors promote a conformational 
change in the 5-HT2A receptors. This conformational change allows increased 
coupling of the 5-HT2A receptor to the g-protein with a concomitant increase in 
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the pathway’s activation.  Introduction of the D2 agonist changes the D2 
receptor’s conformation, which alters the 5-HT2A receptor’s conformation and 
decreases its coupling to the g-protein for a suppressed hallucinogenic response. 
 D2 receptors’ participation with the hallucinogenic pathway is also time 
dependent. In a 2005 study by Marona-Lewicka on dopaminergic responses in 
rats, LSD effects were attenuated by a different antagonist depending on the 
amount of time that passed from the initial dose of LSD.33 In rodents, a 5-HT2A 
receptor antagonist blocks behavior 30 minutes after LSD (LSD-30) while D2 
antagonists are only effective after 90 minutes (LSD-90). Another study by 
Marona-Lewicka in 2007 confirmed this temporal shift in receptor involvement by 
testing a variety of ligands that were specific for either the 5-HT2A receptor or the 
D2 receptor against a LSD-30 or LSD-90 rat.34 The results of this study suggest 
LSD effects are separated into two phases. The first is dictated by serotonergic 
receptors with the second, later phase by dopaminergic receptors. In line with 
these laboratory findings, clinical observations of human LSD experiences reveal 
a temporal change to a more paranoid state at later time points.35 Therefore, this 
theory by Marona-Lewicka suggests a possible serotonergic etiology for the 
symptoms of paranoia and delusions seen in schizophrenia.   
 In addition to glutamate/dopamine receptors and the serotonergic 
pathway, some suggest an endogenous hallucinosis pathway exists that 
contributes to hallucinogenic drug effects. Wallach suggests DMT is an 
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endogenous neurotransmitter with high affinity for trace amine associated 
receptors (TAAR) in the CNS.36 To support DMT being a neurotransmitter, 
sensory alterations only occur with higher concentrations of administered DMT 
that are comparable to the amounts of neurotransmitters released at a synapse. 
These concentrations would be high enough for DMT to activate the TAAR’s in 
the CNS for an endogenous response after overcoming the larger concentrations 
of  5-HT2A receptors. If the DMT-TAAR’s interactions are a neurotransmitter 
system, the unprovoked natural release of this endogenous hallucinogen may 
mediate an altered state of conscious such as near death experiences, out of 
body experiences, and psychosis. When taking an administered hallucinogenic 
drug, Wallach suggests that activation of TAAR’s by DMT is responsible for the 
visual alterations in perception of the hallucinosis experience that are not seen 
with 5-HT2A activation alone. A study by Gouzoulis-Mayfrank saw the effects of 
positive symptoms that represented schizophrenia after giving two doses of DMT 
to 15 healthy participants.37 These doses were large and probably created 
sufficient synaptic concentrations to activate the TAAR endogenous pathway.  
Overall, Wallach’s theory raises new questions about the role of receptors in the 
hallucinogenic pathway and a new avenue of research for psychotherapy.  
Antagonists:        
 Monoamine oxidase inhibitors and selective serotonin reuptake inhibitors 
have been used to attenuate acute LSD hallucinations.38,39,40,41 Similar to the 
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development of LSD behavioral tolerance through continual usage, chronic 
administration of these inhibitors decreases the density of serotonin receptors (5-
HT), which may mitigate behavioral effects of LSD.2  Pre treatment with fluoxetine 
reduced the effects of LSD.  In contrast lithium or Tricyclic anti-depressants 
exacerbate LSD induced hallucinations.40,41 A recent 2013 rodent study suggests 
that clozapine attenuates LSD behavior by down regulating the 5-HT2A 
receptors.42 Used for schizophrenia and bipolar disorders, olanzapine was able 
to reduce the hyperactivity exhibited in rats with chronic LSD injections. 43  
Trials addressing the human clinical pharmacology of LSD have only 
recently resumed. Unfortunately there are limited human serotonergic 
pharmacologic probes that are safe and well characterized. A selective serotonin 
antagonist, m100907, that successfully inhibits LSD behavior in rats46,13 now has 
the name Volinanserin. This drug is undergoing human safety trials for the 
treatment of insomnia and interaction studies between Volinanserin and LSD 
may soon be possible.  Vollenweider et. al has used Ketanserin and Risperidone 
to attenuate the hallucinogenic effects of psilocybin as antagonists. 44  
Neuroanatomy of Hallucinogens:  
Although the anatomic location of LSD action in the CNS is not yet fully 
established, it is clear that a hallucinogenic stimulus is localized to specific 
anatomical sites in the CNS and is not systemic. 
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The anatomical distribution of 5-HT2A receptors is broad with peripheral 
and central expression of receptors. Pyramidal neurons in cortical layer V have 
the highest concentrations of 5-HT2A receptors in the CNS. Activation of these 
neurons in the prefrontal and the anterior cingulate cortex is most likely 
responsible for the altered sensory perceptions induced by hallucinogens.45,46 
When the serotonin antagonist M100907 is infused directly into the anterior 
cingulate cortex of rats, the stimulus effects of systemic LSD are blocked. This 
result supports the anatomic importance of this region in mediating LSD effects.46 
In addition to pyramidal neurons, LSD induces more activation of c-Fos proteins 
in oligiodendrocytes than pyramidal neurons in cortical layer V.47 
Oligiodendrocytes are responsible for maintaining the myelin sheath that is 
essential for rapid signal conduction in neurons. Some recent studies suggest 
that oligiodendrocyte dysfunction is associated with psychiatric disorders like 
schizophrenia, further supporting schizophrenia’s similarities with serotonergic 
hallucinosis.48,49  
In a 2010 psilocybin clinical study, PET scans using a labeled 5-HT2A 
receptor ligand, [18F]altanserin, showed the highest brain activity in the anterior 
cingulate and medial prefrontal cortices.50 This study supports earlier studies by 
Gouzoulis- Mayfrank and Vollenweider that measured regional brain metabolism 
using labeled glucose, (F-18)-fluorodeoxyglucose, in regions of the brain.51,52 
Both these earlier studies saw the greatest brain activity after similar doses of 
 
16 
psilocybin (14-15 mg) in the frontotemporal cortical regions and the anterior 
cingulate.  The anterior cingulate is a brain area that regulates negative and 
positive emotional responses, suggesting that the emotional effects of psilocybin 
are produced by activation of this region. The temporal lobe is involved with 
interpreting visual memories and correlating emotions.  
On the other hand, Carhart’s study challenges the idea that hallucinogens 
cause only an increase in brain activation.53 The focus of his study was to 
analyze the cerebral blood flow in the brain’s transition from a normal, conscious 
state to a hallucinogenic state. In his study, 15 healthy volunteers underwent 
fMRI scanning after being given intravenous saline and then 2 mg of intravenous 
psilocybin. The pattern of cerebral blood flow changed with large decreases in 
activity in the anterior cingulate cortex (ACC), medial prefrontal cortex (mPFC), 
posterior cingulate cortex (PCC) and thalamus that were directly correlated with 
intensity of the user’s altered experience. Carhart suggests that the decoupling 
between the PCC and mPFC is how psilocybin produces hallucinogenic effects 
because these areas had the most consistent decreases in activity after 
psilocybin.  In contrast, activity in these areas increased in placebo conditions. 
The mPFC is important for its ability to inhibit the limbic activity in the brain, 
which modulates the brain’s processing of emotions and links higher cortical 
functions to the autonomic nervous system. It is possible that the mPFC’s 
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decoupling contributes to the depersonalization and perceptual disconnection 
experienced in hallucinosis.  
A follow up study by Carhart focused on the possibility of psilocybin 
facilitating recall of personal memories by increasing activations in brain 
regions.54 Ten healthy participants were given two weeks to create 30 personal 
memories that were integrated with the behavioral analysis. Participants then 
underwent two fMRI scans that were separated by seven days. They received 
intravenous saline for one session and 2 mg of the intravenous psilocybin for the 
next session. Imaging was conducted when subjects were told to perform an 
autobiographical recollection with their eyes closed.  This imaging study revealed 
activations during the recollection period that came in either 8 seconds at the 
beginning (early phase) or 16 seconds at the end (late phase). In the early 
phases, activations were more in the limbic/medial temporal lobe, the striatal 
regions, mid-cingulate cortex, pre-sensorimotor areas, and precuneus. Both 
placebo and psilocybin users experienced similar early phases but differed in the 
late phase of thinking. After placebo, there were late activations in the limbic and 
paralimbic areas. Placebo also produced activation of the medial prefrontal 
cortex and frontal pole. After psilocybin, there was an even greater activation of 
sensory and visual regions (bilateral auditory cortex, somatosensory cortex, 
superior parietal cortex, left visual regions, and occipital pole), which were not 
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active in the late phase of the placebo condition. These increases in sensory 
activity may be the source of the vivid memories induced by hallucinogens. 
 
Hallucinogens in Medicine 
 
Acute Pharmacological Effects of LSD: 
 LSD is highly potent and orally active. Albert Hoffman, the discoverer of 
LSD, took the first known dose of LSD in 1943 when the agent accidently came 
in contact with his skin. The next day, he deliberately repeated the experience 
with a 0.25 mg dose, which is now considered a large dose.  Current estimates of 
illicit doses range from 0.08 -0.025 mg compared to 0.10-0.20 mg range of the 
late 60’s.12 Hallucinogenic experiences that produce anxiety with lower doses are 
less likely to result in adverse effects and the need for medical intervention.12  
LSD is taken orally with an onset of psychological and physiological symptoms 
within 60 minutes.  Peak effects occur between 2-4 hours after administration 
with effects persisting for 10-12 hours.2 Compared to LSD, other serotonergic 
hallucinogens tend to have lesser effects. Psilocybin effects last 4-6 hours 
following 20-30 mg oral doses.55 DMT effects last 30 minutes after 60-100mg 
smoked/injected doses.56  
 In the period of 1 hour-4 hour period after administration, a LSD user 
undergoes a hallucinogenic reaction(“The Trip”), with typical clinical effects of 
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somatic, perceptual, and psychic symptoms. These symptoms recorded by 
Hollister in 1984 are still pertinent to our understanding of LSD interactions with 
the human body (see Table 3).57 Other specific autonomic effects include pupil 
dilation, hyperreflexia, diaphoresis, urinary retention, increase in blood pressure 
and body temperature, piloerection, and tachycardia.1 However, anxiety from 
undergoing this experience is a suspected contributor to these sympathetic 
effects.  
As mentioned earlier, a user often experiences distortions in his sensory 
perceptions and rarely manifests true visual or auditory hallucinations. Users 
often have intensified emotions that can occur at the same time. Many users feel 
that the effects wear off after several hours but develop “paranoid thoughts and 
ideas of reference”.2  Although there is no immediate craving for the drug, there is 
a feeling of fatigue within the next 12 hours after abatement of LSD activity.2 The 
user has a very clear recollection of the drug experience and it is not uncommon 
for users to claim a change in their psyche that leads to challenging concepts of 
their belief system and society.    
In 1967, Cohen stated that death was not “directly caused by the toxicity 
of LSD”.58 This statement remains true more than 50 years later.59, 12 The acute 
cardiovascular, renal and hepatic toxicity of LSD is minimal, possibly because the 
drug has little affinity for the biological receptors that target these organs.12 There 
is no recorded lethal dose in humans and the only reported acute overdose death 
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occurred in an elephant administered a 300 mg dose.  Based on brain weight, 
this dose was ~1,200 times stronger than the dose taken by Hoffman.60 There is 
a single 1971 case report of hemiplegia after LSD, suggesting that LSD can 
produce vasospasms.61 A healthy patient experienced rhabdomyolysis after 
ingesting a moderate but unknown dose of LSD.62  Another report described a 
fibrotic inflammatory mass in the mesentery of a chronic LSD user and multifocal 
cerebral demyelination for a user of psilocybin.63  In general, there is “no 
accepted evidence of brain cell damage, chromosomal abnormalities, or 
teratogenic effects” when using LSD.64,65 
  With other major serotonergic hallucinogens, similar physiological 
symptoms are seen. A recent 2011 study by Griffiths in 18 adult psilocybin users 
saw acute changes in perception and mood. After 7 hours, 39% of participants 
experienced extreme anxiety/fear and 72% of participants had a “mystical” 
experience. The one consistent side effect was a delayed headache in a few of 
the participants. Griffiths conducted a follow up study in 18 participants focused 
on the delayed headache.66 The frequency, severity, and duration of the delayed 
headaches increased with dosing up to 30 mg per 70 kg of psilocybin. Although 
Griffiths cannot confirm the biological cause behind these headaches, he posits 
that delayed headache is due to nitrous oxide release (as seen in animals) and 
this release is mediated by a serotonin receptor. Overall, the major physiological 
 
21 
adverse effects were headaches, which are minimal in comparison to other 
drugs.  
In a pooled study on 8 human psilocybin double blind studies reported 
between 1999-2008, there were no serious physiological complications 
suggesting that psilocybin is well tolerated, similar to LSD.67  In this pool of 110 
subjects, “eight [received] very low doses (45 micrograms/kg), 74 low doses 
(115-125 micrograms/kg), and 41 high doses (315 micrograms/kg)”.67 Three of 
the 110 subjects experienced intense reactions to psilocybin that forced early 
termination of dosing. Two of these subjects left after receiving low doses of 
psilocybin while one subject had a high dose. The authors noted that the high 
dose subject had severe hypotension with blood pressure falling significantly to 
86/66 mmHg.  All adverse effects resolved within 24 hours, including those in the 
three subjects who were terminated due to adverse effects. In general, 
headaches were the most consistent acute side effect followed by a feeling of 
tiredness and exhaustion. Table 1 shows the range of physiological responses 
for psilocybin versus the placebo.  
In all eight studies, psilocybin consistently produced hallucinogenic effects 
such as visual distortions. The analysis notes that participants experienced a 
range of visual changes from “increased visual imagery with closed eyes, optical 
illusions, elementary hallucinations and synesthesia to picture like scenery 
hallucinations”.67 Further analysis of the psychological changes revealed that 
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subjects were able to differentiate between psilocybin-induced alterations and 
reality. Auditory sensations were only moderately affected and true auditory 
hallucinations were rare. Interestingly, there were dose dependent decreases in 
measures of drowsiness, alertness, and cognitive function within 24 hours of 
drug administration. The authors note that the small sample size in Griffith’s may 
explain the relatively high (39% of its participants) rate of paranoia and fear 
experienced by subjects. In this study, participants received 30 mg per 70 kg or 
429 micrograms per kg which is about the same as the “high dosing” category of 
this pooled study. However, in contrast to other investigators, Griffith’s 
participants were not experienced hallucinogen users.  The lack of prior 
experience coupled with the high dose may better explain these results. For more 
detailed descriptions of acute serotonergic hallucinosis experiences, there is 
extensive scientific documentation by Hollister and Griffiths and several personal 
accounts on the Erowid website. 
 Despite the low frequency of acute physiological complications from 
serotonergic hallucinogens, dangerous behavior can occur in intoxicated users.68 
As a long acting serotonergic drug, LSD can produce paranoia. When combined 
with the user’s alterations in perception, LSD can create a “bad trip” with severe 
anxiety. Therefore, it is plausible that users might make poor decisions or 
endanger themselves. However, despite societal believes that LSD can cause 
people “to fly out of windows”, LSD is rarely, if ever, the primary factor in a 
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suicide. Media coverage of suicides by prominent individuals such as Diane 
Linkletter and Frank Olson shaped public perception towards the danger of LSD. 
Diane Linkletter was the daughter of a well-known entertainer. In her case, LSD 
was not found in post mortem toxicology testing but her grieving father claimed 
LSD was responsible for her death. He would use the tragedy to fuel the fight for 
tighter restrictions in the War on Drugs.69 Frank Olson was a biological warfare 
specialist working for the U.S. Central Intelligence Agency. He was apparently 
dosed without his knowledge and fell out of a window nine days later. Post 
mortem toxicology was negative for LSD.  The autopsy was also remarkable for 
severe trauma that was not consistent with the fatal fall70, raising the possibility 
that his death was not a suicide but rather a homicide.  
The Drug Abuse Warning Network (DAWN) obtains reports of emergency 
department visits from hospitals and drug-related deaths from medical 
examiners. Emergency department visits due to LSD and other hallucinogens are 
rarely reported in DAWN but there are sporadic reports of deaths.71 Although 
DAWN has a category for hallucinogens most of the drugs in their grouping are 
not serotonergic hallucinogens. LSD usage is reported together with several 
other hallucinogenic drugs including phencylidine.  Most localities report no 
hallucinogen-associated deaths.  However, in Maryland there were 16 
hallucinogen-associated deaths in 2009 and 8 deaths in 2010.  In Virginia, there 
were 5 deaths in 2010.71 There were no hallucinogen-associated suicides 
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reported in DAWN. Overall, deaths due to hallucinogens are uncommon and 
appear to occur in clusters. The mechanisms of death are also not well 
documented but may be due to contaminants or other local factors. 
Risk of Addiction: 
 Repeated use of LSD results in tolerance and cross-tolerance with other 
serotonergic hallucinogens, which suggests their mechanisms of tolerance 
development follow similar pathways.2 However, LSD is not considered addicting. 
Behavioral tolerance develops quickly after a few days of administration and this 
tolerance disappears if drug use is discontinued for some period of time.  
Therefore, users take LSD 1-2 times spaced over a week.72 Although tolerance 
develops to the psychological effects of mood alterations and visual 
hallucinations, less tolerance seems to develop to autonomic effects.  There are 
no withdrawal symptoms after terminating repeated usage, suggesting a low risk 
for addiction.2  
Long Term Adverse Effects: 
Hallucinogen Persisting Perception Disorder  (HPPD) is the only 
recognized long term complication of LSD use. Also known as “flashbacks”, 
HPPD is the return of physiological and psychological symptoms from the original 
drug experience but without use of the triggering drug.  Chronic hallucinogen 
users may have an increased risk of developing Hallucinogen Persisting 
Perception Disorder. From the revised 4th edition of the Diagnostic and Statistic 
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Manual of Mental Disorders, HPPD is categorized under this following set of 
criteria:73 
 
“Diagnostic criteria for 292.89 Hallucinogen Persisting Perception Disorder 
(Flashbacks) 
A. The re-experiencing, following cessation of use of a 
hallucinogen, of one or more of the perceptual symptoms that were 
experienced while intoxicated with the hallucinogen (e.g., 
geometric hallucinations, false perceptions of movement in the 
peripheral visual fields, flashes of color, intensified colors, trails of 
images of moving objects, positive afterimages, halos around 
objects, macropsia, and micropsia).  
B. The symptoms in Criterion A cause clinically significant distress 
or impairment in social, occupational, or other important areas of 
functioning.  
C. The symptoms are not due to a general medical condition (e.g., 
anatomical lesions and infections of the brain, visual epilepsies) 
and are not better accounted for by another mental 
disorder (e.g., delirium, dementia, schizophrenia) or hypnopompic 
hallucinations.” 
In examining the DSM’s criteria, the specific visual alterations listed reflect 
the most common disturbances noted in Abraham’s 1983 study of 123 LSD 
users.74 Abraham described several abnormalities in visual processing. He noted 
that HPPD patients have difficulty adjusting to the darkness.  HPPD patients also 
detect flickering lights at a lower critical frequency than a normal person. 
Kilpatrick suggests the visual processing abnormalities described by Abraham 
are likely due to faulty synaptic connections in the brain. Kilpatrick’s study 
supports this idea with a computational theoretical model to explain how HPPD 
users experience trailing phenomena and halos.75 This model encourages future 
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human studies into the visual alterations of HPPD including a recent fMRI study 
on a patient with a severe case of HPPD. This fMRI study measured areas of 
visual function in a patient who saw a manifestation of faces on any tree.76 
Results suggested specific cortical regions involved in the pathway of normal 
facial processing that are targeted by hallucinogens.      
 Although repeated use may increase the risk, HPPD has been described 
after only one exposure to LSD.77  A 2011 web questionnaire of 2455 participants 
enrolled from the Erowid website concluded that 60.6% had drug-free visual 
experiences that resembled hallucinogenic effects but only 4.2% found them 
distressing enough to seek help.78 Although these data describe participants who 
had used several hallucinogenic drugs, the prevalence of visual experiences in 
non-LSD users was 18.1% compared to 34.5% who used LSD. Currently, there 
is no defined range of HPPD severity but this survey suggests the possibility of a 
higher rate of HPPD with LSD use. Fortunately, the incidence of diagnosed 
HPPD appears to be very small, but because millions of people have used 
hallucinogens, absolute numbers may be higher than commonly thought.12 
Overall, the understanding of HPPD triggers is limited because there is still no 
clear mechanism of LSD’s influence on the brain.   
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Treating Complications of Hallucinogen Use 
 LSD often produces substantial anxiety but severe complications requiring 
hospitalization or causing death are uncommon.  Because no safe or specific 
antagonist is available, treatment of severe intoxication or an acute adverse 
reactions is symptomatic.  Hallucinogen-associated anxiety can be treated by 
sedation with benzodiazepines.  Despite the interest in LSD as a 
psychotomimetic, hallucinogens only rarely produce more than transient 
episodes of thought disorder.  Some recommend using phenothiazines such as 
haloperidol to treat acute LSD induced psychosis.79 However, use of 
antipsychotics should be approached with caution due to a potential paradoxical 
increase in psychotomimetic effects with non-hallucinogens like phencyclidine 
(PCP) and 2,5-Dimethoxy-4-methylamphetamine (DOM). Therefore, if the drug is 
unknown or not a hallucinogen, benzodiazepines may be safer and just as 
effective.44 
Patients occasionally seek treatment for Hallucinogen Persisting 
Perception Disorder but pharmacological management can be unsatisfying.  
Treatment with serotonin reuptake inhibitor antidepressants or dopaminergic 
antagonists such as risperidone have reportedly induced or worsened 
symptoms.80,81,82 Mechanistically, increased synaptic serotonin may activate 
sensitized 5-HT2A neurons and their associated circuits, increasing symptoms. 
Some benefit has been seen with the centrally acting alpha 2A agonist clonidine 
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and the benzodiazepine clonazepam, or a combination of fluoxetine and 
olanzapine.83,84 Most treatment options include sedatives, which may be effective 
due to non-specific sedation rather than impacting specific pharmacologic 
disruptions induced by LSD. Non-pharmacological avenues such as “talk down 
therapy”, which works by openly addressing and reassuring a user’s symptoms 
and anxiety, should be used in addition to these options for acute and chronic 
adverse events. 
 
Epidemiology  
In the United States, abuse of LSD decreased from peak levels in the 
1960’s likely due to limited availability. It started to climb in the 1990’s with usage 
increasing in young adults, and, more specifically high school students.2 A 
reliable source for surveying this demographic is the annual Monitoring the 
Future study (MTF) that samples 45,400 students in 8th,10th, and 12th grade for a 
national consensus of drug use in high school students.85 At its peak in 1997, the 
prevalence of LSD was 6.0% in high school students. The lifetime prevalence 
rate was 9.0% for LSD versus 5.0% with other hallucinogens. Ethnic differences 
were observed in these 1990’s data that showed a higher rate of usage amongst 
high school Caucasians than African Americans or Hispanics.85 However, LSD 
usage peaked around this time and there has been a decline in LSD usage 
starting in 1996 to the present.  
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In the most recent 2012 MTF study, high school students found that LSD 
was only “fairly accessible”, with 27.6% of 12th graders, 14.9% of 10th graders, 
and 7.5% of 8th graders reporting that they can obtain LSD easily85 (see Figure 6). 
The combined annual prevalence rate of combined 8th,10th, and 12th graders has 
decreased from 2.4% in 2002 to 1.6% in 2012 and this change in annual 
prevalence has fluctuated only marginally in the last 9 years (see Figure 4). 
However, the use of other hallucinogens such as psilocybin has increased with 
annual prevalence rates of 3.1% in 2011 and 2.7% in 2012. Many 12th graders 
rate psilocybin as more available than LSD, possible explaining the increased 
prevalence of psilocybin use.  The MTF study also suggests that LSD use has 
been in a steady decline ever since the closing of a major synthesizing laboratory 
by the DEA in 2000. Ironically, the declining prevalence of LSD use has been 
accompanied by a fall in ratings of disapproval and perceived risk suggesting that 
the decline in use is more a function of availability than perceived risk (see Figure 
5). The MTF study calls this “generational forgetting”. Unfortunately, it could set 
the stage for a possible revival with a new generation wave that seeks something 
different to experiment with.  
The National Survey on Drug Use and Health surveys 67,500 people ages 
12 years and older to estimate use of illicit drugs in the total U.S. population.  The 
2011 results from this broader population survey suggest new LSD use is rising 
but not as sharply as other drugs like MDMA.86  The NSDUH estimated that 
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358,000 people initiated use of LSD in 2011 (see Figure 8).  In contrast, 922,000 
are estimated to have initiated MDMA during this period. This number of LSD 
initiates is similar to 2009 but higher than in 2003-2007 where there were 
200,000-270,000, respectively.86 From 2002 to the present, hallucinogen use has 
remained relatively stable with only a small increase in LSD use.  Youth 12 and 
older and adults perceive LSD as ‘fairly accessible’; (12.9%); this has declined 
from 19.4% in 2002 (see Figure 7). In general, 972,000 people (.4% of the U.S. 
population) of the sampling ages 12 and older were using hallucinogens in the 
past month, which is lower than 1.2 million (.5%) who were using in 2010. The 
use of hallucinogens from ages 12-17 was highest in the range between 16 and 
17 years old which aligns well with the Monitoring the Future study. Like many 
other abused drugs, hallucinogen use is more common in emerging adults with 
ages between 16 and 19 years of age. Some interesting observations reported in 
this NSDUH review include gender and ethnic differences in LSD use where the 
most prevalent use of LSD was seen in female Caucasians and Native 
Americans. Use was also common as a “club drug”, a label coined by the 
National Institute on Drug Abuse. In this context, data suggests that LSD is 
commonly used by young adults at bars, clubs, concerts, and parties.87  The 
narrow age demographic of hallucinogen use suggests that the transition point 
for use is graduating from high school, starting a career, going to college, or post 
secondary school. In general, it is clear that LSD has more of a following 
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amongst youth but the population abusing LSD may have stabilized while other 
more accessible hallucinogens like psilocybin are on a rising trend.   
 
Relation to Schizophrenia 
The relationship between LSD use and development of schizophrenia is 
complex. It is unclear if LSD precipitates psychosis or merely exposes psychosis 
that was already present.12 Because LSD produces hallucinosis and disordered 
thinking, some have hypothesized that similar mechanisms may underlie 
development of schizophrenia. Hoffman was the first to note that the 
psychtomimetic effects of LSD were analogous to the behaviors seen in 
schizophrenia.12 From the positive experience of heightened senses and euphoria 
to the negative experiences such as paranoia and anxiety, the range of effects 
seen in serotonergic hallucinogenic users are more similar to earliest phases of 
schizophrenic psychoses than the chronic phases (see Table 2).88 Other 
similarities are seen on a neurological level with common hyperfrontal metabolic 
patterns between 5-HT2A receptor activation and acute schizophrenia or 
psychosis.89  Vollenweider and Geyer hypothesized that serotonergic 
hallucinogens stimulate 5-HT2A receptors in the cortico-striato-thalamo-cortical 
feedback loops to disrupt thalamo-cortical transmission.90  The thalamic gating of 
sensory and cognitive information is disrupted which leads to an overflow of 
stimuli in the cortex seen in early stages of schizophrenia.   
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 Carhart’s 2011 study also proposes a model of early schizophrenia that 
involves what he terms the Default Mode Network (DMN). This network is 
composed of the posterior cingulate cortex, medial prefrontal cortex, and lateral 
inferior parietal cortex and is responsible for high level, internal cognition like 
introspection, envisioning the future, or moral judgments. 91 High levels of blood 
flow through the DMN network suggest that it consumes large amounts of 
energy. Although not localized, a competing brain network that Carhart identifies 
is the Task-Positive Network (TPN), a network that processes goal-oriented 
tasks. As competing networks, DMN and TPN have an inverse relationship with 
one being activated while the other is switched off during cognitive activity. To 
test these theories, Carhart conducted a within-subject placebo-controlled study 
of CNS activity comparing psilocybin to placebo using blood oxygen level 
dependent (BOLD) CNS fMRI. They found that psilocybin activated both the DPN 
and TPN but the placebo activated only one network. Based on these 
observations, Carhart suggests that the co-activation of these reciprocal 
networks blurs the boundary between a person’s internal self and the 
environment leading to ego dissolution, a sign that may accompany early 
psychosis and schizophrenia.     
 There are differences between the thought disorder produced by 
serotonergic hallucinogens and the psychosis in a schizophrenic patient.  Most 
importantly, schizophrenia has a life long progression whereas rapid tolerance 
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develops to the psychopharmacological effects of serotonergic hallucinogens.  
Another difference is that schizophrenic patients often experience auditory 
hallucinations whereas serotonergic hallucinogens primarily produce visual 
hallucinations.88 Yet, there is some evidence showing that visual hallucinations 
are experienced in the acute and incipient stages in schizophrenic patients, 
which supports the claim that serotonergic hallucinations mimic early 
schizophrenia.88 Current evidence suggests that early schizophrenia is dominated 
by serotonergic abnormalities.88 However, as the schizophrenic disorder 
progresses, the brain compensates by involving dopaminergic and glutamatergic 
systems, which explains the striking differences between chronic schizophrenia 
and acute schizophrenia or serotonergic hallucinosis.  
A recent rodent study by Marona-Lewicka induced symptoms of chronic 
schizophrenia through long-term administration of low LSD doses.43 After giving 
.16 mg/kg every other day for 3 months, the rats exhibited “hyperactivity and 
hyperirritability, increased locomotor activity, anhedonia, and impairment in social 
interaction that persist[ed] at the same magnitude for at least three months after 
cessation of LSD treatment”.43 These symptoms resembled chronic schizophrenia 
in rat models. A specific 5-HT2A antagonist did not attenuate these chronic 
symptoms. However, haloperidol and olanzapine, D2 / 5-HT2A receptor 
antagonists/ inverse agonists, did decrease abnormal behaviors. Since 5-HT2A 
receptor antagonists can attenuate an acute LSD episode in rodents13, these 
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results suggest a neuro-adaptive progression from serotonin receptors to other 
receptor types with frequent LSD exposure. Marona-Lewicka believes this 
method of chronic LSD exposure is the best technique for creating schizophrenic 
animal models, adding more support to the link between schizophrenia and LSD.  
 
Potential Therapeutic Uses of Serotonergic Hallucinogens 
 With its potential to induce positive experiences through an altered 
perception of reality, serotonergic hallucinogens such as naturally occurring 
psilocybin have become integrated into religious cultures. Psilocybin was used in 
Aztec and Mayans rituals as a rite of passage or as an opportunity to evoke 
visions in the spiritual realm, ultimately leading to a change the user’s outlook on 
life.92 Although the initial studies with serotonergic hallucinogens did not seek to 
evoke spiritual experiences, recent studies have attempted to study the biological 
basis of spiritual experiences.  This work started with studies of LSD in treatment 
of psychological disorders. For example, LSD can decrease anxiety and improve 
emotional well-being in terminally ill patients.93,94 Studies conducted at the Spring 
Grove State hospital in Maryland found improvements in two thirds of their 
terminal cancer patients, which allowed for a reduction in doses of pain 
medication.95,96 Unfortunately, these studies were terminated as a consequence 
of widespread abuse of LSD.  Recently, studies in end of life care have resumed. 
Grob and colleagues showed that a moderate dose 0.2 mg/kg dose of psilocybin 
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decreased anxiety in 12 advanced stage cancer patients.97  Grob states that after 
psilocybin, many patients “no longer considered themselves as being overly, 
anxious or worried people”.97 
 Case reports suggest that hallucinogens may be useful in treating 
Obsessive-Compulsive disorder (OCD).  In a 1962 report by Savage et al., one 
patient experienced a dramatic improvement after two unspecified doses of 
LSD.98  In another early study by Brandrup and Vanggaard, weekly LSD 
treatments for 15 months produced a steady resolution of symptoms. Patients 
were symptom free 3 years post-treatment.99 There are several other reports that 
provide case evidence of serotonergic hallucinogens’ efficacy in treating 
OCD.100,101,102 Studies on the efficacy of psilocybin for anxiety are underway at 
John Hopkins and New York University.  
 Another focus of serotonergic hallucinogens on psychological disorders is 
addiction such as alcoholism.  In a 1971 review of 31 studies from 1953-1969 
with data from 1,100 alcoholics, no definitive statements of LSD’s impact on 
alcoholism could be made because of the wide range in study designs, 
outcomes, dosages and definitions of alcoholism.103 Nonetheless, in one study at 
the 10-month follow up, a single dose of LSD produced improvement in 75% of 
treated patients versus 44% of the controls.103  For subjects receiving multiple 
doses of LSD, 58% were improved at a 20 months versus 54% of controls.  
Krebs and Johansen performed a retrospective analysis of data from six 
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randomized, controlled trials where participants were dosed once with up to .05 
mg of LSD; notably these trials excluded patients with severe psychiatric 
illness.104 They observed a significant beneficial effect of a single LSD dose on 
alcohol misuse and saw a significant improvement from 2 to 6 months post 
treatment.  However, effects dissipated by 12 months, suggesting that additional 
doses of LSD may be necessary.104 When LSD is compared to treatment with 
approved medications like naltrexone, acamprosate, or Disulfram, comparable 
efficacy is seen. Although limited, these data suggest single doses of LSD 
dosage are comparable to chronic treatment with approved medications in 
reducing alcohol abuse relapses.  
 DMT has also been suggested as a therapeutic for alcoholism. As the 
active ingredient in the herbal brew called Ayahuasca, South American treatment 
centers have incorporated Ayahuasca in to their programs. Ayahuasca is a 
mixture of a DMT containing shrub species from the Psychotria genus with 
monoamine oxidase inhibitors from the caapi vine. The monoamine oxidase 
inhibitors are important for this concoction because they prevent DMT from being 
metabolized in the gut.5  A pilot study by Mckenna’s Hoasca Project gathered 
data on the psychological effects of Ayahuasca in the Amazon basin.5 This study 
reported that Ayahuasca use was widespread in males and females of 13-90 
years of age. Before using Ayahuasca, many of the people interviewed by 
Mckenna reported they were engaged in risky behavior such as violence, 
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spousal abuse, infidelity, and alcoholism. Their use of Ayahuasca, along with 
religious guidance from local shamans, invoked terrifying experiences that led to 
self-realization and a motivation to change, resulting in positive life 
improvements.  Recently, a large collection of anecdotal reports from Metzner 
suggests that Ayahuasca has potential psychotherapeutic effects when 
administered in a controlled environment.105 Although the documented effects of 
Ayahuasca have been subjective experiences, there are an increasing number of 
South American physicians and patients who support a more thorough 
investigation into the compound’s efficacy. 
Currently, studies of hallucinogens’ psychological effects are being 
conducted at several centers.  Notably, Griffiths and Johnson are using 
psilocybin to supplement cognitive behavioral therapy for smoking cessation.106 
Overall, the idea of treating addiction with hallucinogens is becoming more 
rational as new neuroimaging and pharmacological techniques allow for a deeper 
analysis of drug effects.  
Studies suggest LSD and psilocybin can be used to treat cluster 
headaches. Sewell interviewed cluster headache patients who had used LSD or 
psilocybin to treat their disease.107 Twenty-two of 26 psilocybin users reported 
that psilocybin aborted an acute attack. Twenty-five of 48 psilocybin users and 7 
of 8 LSD users reported cluster period termination. Eighteen of 19 psilocybin and 
4 of 5 LSD users reported an extension of their remission time. These survey 
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numbers are very encouraging. A preliminary, clinical study using a non-
hallucinogenic analogue of LSD (2-bromo LSD) reported positive results in 5 
patients.108 This study, by Karst, used three oral doses of 2-bromo LSD over 10 
days to terminate the cluster headache period or improve the patient’s 
symptoms. Three of the patients went into a prolonged remission after the 2-
bromo LSD treatment. Although this study has encouraging results, 2-bromo 
LSD’s does not activate 5-HT2A or 5-HT1A receptors.109 Thus, serotonergic 
modulation may not be the mechanism of action in the efficacy these drugs in 
cluster headache. From the results of this preliminary study and Sewell’s survey, 
more studies in cluster headache with serotonergic drugs and their analogues 
are a possibility. 
 
Conclusion  
Having minimal adverse effects in humans and a powerful influence on the 
human psyche, LSD was a fascinating tool for neuroscientists in the 1950’s. 
Although the methods and designs of clinical trials have changed over the last 60 
years, these early studies provided direction and inspiration for further research 
on serotonergic hallucinogens. More recent studies have focused on 
mechanisms of action, associations with disease states and possible therapeutic 
applications. LSD is the prototype of the serotonergic hallucinogen class but its 
long duration of action and its powerful psychopharmacological effects may make 
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LSD less attractive as a therapeutic when compared to shorter acting drugs like 
DMT or less powerful agents like psilocybin. Other widely abused drugs are also 
being ‘rehabilitated’ and considered for therapeutic uses.  There are also pilot 
studies into the effects of MDMA in treating Post Traumatic Stress Disorder, 
Ibogaine (psychoactive alkaloid) for opioid addiction, and Ketamine for cocaine 
dependence.110 Hopefully, these studies will revitalize an area of research that 
has been stagnant for more than 40 years in the United States. The use of 
hallucinogens can possibly change how we address some of psychiatry’s most 
complex problems. By biologically mapping our emotions and cognitive 
processing through receptors, neurotransmitters, and specific brain regions, 
research with hallucinogens can increase our understanding of the human mind. 
Understanding hallucinogens provides a scientific underpinning for some of the 
most profound human experiences such as mysticism, creativity and craziness. 
The human psyche is one of the frontiers in medicine and research with 
hallucinogens brings us closer to understanding its complexities.  
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Figures: 
 
 
Figure 1- A 2-D molecular structure of D-Lysergic Acid Diethylamide. Figure downloaded from 
Erowid111 
 
 
 
 
 
 
 
  
Figure 2- A 2-D molecular structure of Psilocybin. Figure downloaded from Erowid.111 
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Figure 3- A 2-D molecular structure of N,N-DMT. Figure downloaded from Erowid.111 
 
 
 
 
Figure 4: Percentage of 8th, 10th, and 12th graders who used LSD in the last 12 months. This graph 
shows the peak use of LSD in the mid 1990’s that is followed by a steep decline. In the last 4 years, 
the use of LSD has stabilized among youth.  Figure taken from Johnston et al, 2012.85 
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Figure 5: Percentage of 8th, 10th, and 12th graders who saw a “great risk” in using LSD once or twice. 
This graph shows a declining trend in the youth’s perception of LSD as a “risky” drug. The decline 
sees a steady drop around the mid 1990’s that correlates with the decline of LSD availability and the 
possibility of “generational forgetting” from LSD’s lack of presence. Figure taken from Johnston et 
al, 2012.85 
 
Figure 6: Percentage of 8th, 10th, and 12th graders who saw LSD as “fairly easy” or “very easy” to 
obtain. This graph shows a declining trend of LSD availability since the mid 1990’s, which may lead 
to “generational forgetting”. Figure taken from Johnston et al, 2012.85  
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Figure 7: Percentage of people aged 12 and older who think LSD is “fairly” or “very easy” to obtain 
from 2002 to 2011. This graph shows a steady downward trend of LSD availability from 2002 that is 
much lower than other illicit drugs. Figure taken from Substance Abuse and Mental Health Services 
Administration 2011.86   
 
 
 
 
Figure 8: The number of hallucinogen initiates among people 12 years and older from 2002 to 2011. 
The number of LSD initiates is on a rising trend from 2003 that peaked in 2008 and base lined in 
recent years. However, the number of LSD initiates is much lower compared to “other 
hallucinogens” that may be more available. Figure taken from Substance Abuse and Mental Health 
Services Administration 2011.86   
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Figure 9: Theoretical diagram of allosteric influence between 5-HT2A receptor and D2 receptor. On the 
far left, the 5-HT2A receptor binds to an agonist (DOI) and then couples to Gq/11 protein for synthesis 
of hallucinogenic response. In the middle, the D2 receptor binds to the 5-HT2A receptor and 
decreases DOI affinity but increases the coupling between the 5-HT2A receptor and Gq/11 protein. On 
the far right, quinprole activates the D2 receptor and causes increased DOI affinity but decreased 
Gq/11 protein. Figure taken from Albizu 2011. 32 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
45 
Tables: 
 
Table 1: List of complaints 24 hours after psilocybin intake. From the pooled study of 110 subjects, 
the top three complaints are fatigue, exhaustion, and headaches that were more frequent with dose 
increases. Table taken from Studerus et al 2011.67  
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Table 2: Symptoms in psychotic disorders and hallucinogen states. The disorder of emotion and 
perceptual disturbances are very similar to the basic dimensions of a hallucinogenic state. Table 
taken from Geyer et al. 2008.88 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
47 
Table 3: Typical clinical symptoms of LSD users according to Hollister in 1984. These symptoms are 
still relevant to our understanding of LSD’s interactions with the human body. Data taken Hollister et 
al. 1984.57 
 
Somatic 
Symptoms 
dizziness, weakness, tremors, nausea, 
drowsiness, paresthesias, and blurred 
vision.  
Perceptual 
Symptoms 
altered shapes and colors, difficulty in 
focusing on objects, sharpened sense of 
hearing, and rarely synesthesias. 
Psychic  
Symptoms 
alterations in mood (happy, sad, or irritable 
at varying times), tension, distorted time 
sense, difficulty in expressing thoughts, 
depersonalization, dreamlike feelings, and 
visual hallucinations. 
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